Denali CEO to Highlight Blood-Brain Barrier Breakthroughs at AAIC 2026
Event summary
- Denali CEO Ryan Watts to deliver opening plenary at AAIC 2026 in London on July 12, 2026.
- Denali's TransportVehicle™ technology received FDA accelerated approval for AVLAYAH™ in March 2026.
- DNL628 (OTV:MAPT) and DNL921 (ATV:Abeta) are in clinical development for Alzheimer’s disease.
- Phase 1b data for DNL628 expected in 2027; Phase 1/1b trial initiation for DNL921 pending regulatory approval.
The big picture
Denali Therapeutics is positioning itself as a leader in overcoming the blood-brain barrier challenge, a critical hurdle in neurodegenerative disease treatment. The company's proprietary TransportVehicle™ platform has already secured FDA approval for AVLAYAH™, setting the stage for its Alzheimer’s-focused pipeline. With DNL628 and DNL921 advancing through clinical trials, Denali aims to capitalize on growing demand for effective biologic therapies targeting tau and amyloid beta pathologies.
What we're watching
- Clinical Progress
- Whether Denali can deliver positive Phase 1b data for DNL628 and initiate trials for DNL921 as planned in 2027.
- Regulatory Dynamics
- How the FDA’s accelerated approval pathway will impact Denali’s broader pipeline beyond AVLAYAH.
- Competitive Positioning
- The pace at which Denali can differentiate its TransportVehicle™ technology in the crowded Alzheimer’s disease space.
Related topics